Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669920 | 0.87 | BCL2L1 (0.47) | ALDH1A1CTSSBCL2L1MCL1 | |
| SCHEMBL6668702 | 0.86 | BCL2L1 (0.46) | ALDH1A1L3MBTL1CTSSBCL2L1MCL1 | |
| SCHEMBL6667289 | 0.83 | BCL2L1 (0.46) | ALDH1A1L3MBTL1CTSSBCL2L1MCL1 | |
| SCHEMBL6664357 | 0.80 | CTSS (0.44) | ALDH1A1CTSSBCL2L1MCL1 | |
| SCHEMBL7346856 | 0.80 | PDPK1 (0.49) | BCL2L1MCL1GSK3BHDAC1HDAC8 | |
| SCHEMBL10918323 | 0.76 | POLB (0.60) | ALDH1A1MAPTSMN1; SMN2POLBEPHX2 | |
| SCHEMBL728368 | 0.76 | ALDH1A1 (0.49) | ALDH1A1MAPTSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL1304895 | 0.75 | ALDH1A1 (0.56) | ALDH1A1MAPTSMN1; SMN2POLBEPHX2 | |
| SCHEMBL5197841 | 0.75 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2POLBEPHX2 | |
| SCHEMBL5194943 | 0.75 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2EPHX2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897644-B2 | Antiinflammatory agents; analgesics | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-01 | — | — | US | claimed |
| US-20100273872-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | claimed |
| EP-2214659-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | Merck Patent GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009071161-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2009-06-11 | — | — | WO | claimed |
| EP-1450780-B1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GMBH (DE) | 2007-03-07 | — | — | EP | claimed |
| EP-1448181-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2006-05-31 | — | — | EP | claimed |
| US-20050085489-A1 | Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-04-21 | — | — | US | claimed |
| US-20050070553-A1 | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-03-31 | — | — | US | claimed |
| US-20050020609-A1 | Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | claimed |
| US-20050014768-A1 | Use of 4-oxobutanoic acid derivatives in the treatment of inflammation | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-1463503-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GmbH (DE) | 2004-10-06 | — | — | EP | claimed |
| EP-1458412-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GmbH (DE) | 2004-09-22 | — | — | EP | claimed |
| EP-1450780-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| WO-2003057216-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2003-07-17 | — | — | WO | claimed |
| WO-2003055523-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2003-07-10 | — | — | WO | claimed |
| WO-2003047574-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DERIVATIVE OF 5-PHENOXYALKYL-2,4-THIAZOLIDINEDIONE TYPE AND A 4-OXOBUTANOIC ACID | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003047561-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | claimed |
| EP-0925273-B1 | PHARMACEUTICAL COMPOSITION CONTAINING 4-OXO-BUTYNIC ACIDS | MERCK PATENT GMBH (DE) | 2001-11-07 | — | — | EP | claimed |
| US-6143787-A | HETEROCYCLIC OR AROMATIC OXOACIDS | MERCK PATENT GESELLSCHAFT MIT (DE) | 2000-11-07 | — | — | US | claimed |
| US-7897644-B2 | Antiinflammatory agents; analgesics | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20100273872-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2214659-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | Merck Patent GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| US-7727977-B2 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-01 | — | — | US | disclosed |
| WO-2009071161-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2009-06-11 | — | — | WO | disclosed |
| EP-1450780-B1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GMBH (DE) | 2007-03-07 | — | — | EP | disclosed |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1448181-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2006-05-31 | — | — | EP | disclosed |
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | MERCK PATENT GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1581215-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581216-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050085489-A1 | Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| US-20050070553-A1 | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20050020609-A1 | Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| US-20050014768-A1 | Use of 4-oxobutanoic acid derivatives in the treatment of inflammation | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| EP-1463503-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GmbH (DE) | 2004-10-06 | — | — | EP | disclosed |
| EP-1450780-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2004060368-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060369-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
| WO-2003057216-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003047574-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DERIVATIVE OF 5-PHENOXYALKYL-2,4-THIAZOLIDINEDIONE TYPE AND A 4-OXOBUTANOIC ACID | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003047561-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | disclosed |
| US-6143787-A | HETEROCYCLIC OR AROMATIC OXOACIDS | MERCK PATENT GESELLSCHAFT MIT (DE) | 2000-11-07 | — | — | US | disclosed |
| US-6143787-A | HETEROCYCLIC OR AROMATIC OXOACIDS | MERCK PATENT GESELLSCHAFT MIT (DE) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020609-A1 | Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes | GPR119, IAPP, SLC5A1 | ALDH1A1 1290/4885MAPT 2524/4885SMN1; SMN2 1770/4885 |
| US-20100273872-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | ABAT, HOGA1, IL4I1 | ALDH1A1 226/4885MAPT 2710/4885SMN1; SMN2 1065/4885 |
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | KYNU, KMO, IDO1 | ALDH1A1 1018/4885MAPT 3894/4885SMN1; SMN2 4651/4885 |
| US-20050070553-A1 | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes | GANAB, GAA, GANC | ALDH1A1 436/4885MAPT 2233/4885SMN1; SMN2 2829/4885 |
| US-20050014768-A1 | Use of 4-oxobutanoic acid derivatives in the treatment of inflammation | IL1B, HCAR2, IL6 | ALDH1A1 453/4885MAPT 1669/4885SMN1; SMN2 3170/4885 |
| US-20050085489-A1 | Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes | SLC5A1, DPP4, SLC5A2 | ALDH1A1 552/4885MAPT 1776/4885SMN1; SMN2 3045/4885 |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | KYNU, KMO, AADAT | ALDH1A1 705/4885MAPT 4129/4885SMN1; SMN2 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.